MedPath

The Comparative Effectiveness Dementia & Alzheimer's Registry

Conditions
Mild Cognitive Impairment
Alzheimer Disease
Registration Number
NCT03687710
Lead Sponsor
Weill Medical College of Cornell University
Brief Summary

To evaluate the effectiveness of using clinical precision medicine to develop lifecourse interventions for Alzheimer's disease (AD) prevention and treatment. Anthropometrics, blood biomarkers (including genetics), and cognition will measured longitudinally to assess the comparative effectiveness of clinical care.

Detailed Description

The Comparative Effectiveness Dementia \& Alzheimer's Registry (CEDAR) Project is a prospective, observational registry of adult patients at-risk for, or with, a diagnosis of dementia due to Alzheimer's disease (AD) or other neurodegenerative dementias. The purpose of this study is to develop a research repository, or database, for information collected during routine medical care of people with normal memory and family history of AD, or with memory loss or other changes in thinking. The registry will help generate empirical evidence that improves knowledge and informs care decisions about risk reduction for dementia due to AD, and about the effectiveness of a clinical precision medicine intervention. Using a life course approach to comparative effectiveness research will enable investigators to analyze the effects of evidence-based multidomain interventions on cognition, biomarkers of AD risk, and calculated AD risk across the pre-dementia spectrum of AD.

Recruitment & Eligibility

Status
ENROLLING_BY_INVITATION
Sex
All
Target Recruitment
452
Inclusion Criteria
  • 18 years of age or older
  • family history of Alzheimer's disease and no cognitive complaints OR subjective cognitive decline OR preclinical AD OR mild cognitive impairment due to AD or other conditions
Exclusion Criteria
  • none

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Change from Baseline in Alzheimer's Prevention Initiative Cognitive Composite (APCC) every 6 monthsevery 6 months, for 18 months

Composite Cognitive Battery (including NIH Toolbox Cognition Battery and other pen-and-paper neuropsychological tests).

Secondary Outcome Measures
NameTimeMethod
Change from Baseline on Multi-Ethnic Study of Atherosclerosis (MESA) Risk Percentage at 18 months.18 months

Measure longitudinal changes in a validated cardiovascular risk scale (higher percentage confers higher risk).

Change from Baseline in Homocysteine at 18 months18 months

Change in blood serum level of homocysteine

Change in Baseline on Cardiovascular Risk Factors, Aging, and Incidence of Dementia (CAIDE) Risk Score at 18 months18 months

Measure longitudinal changes in a validated Alzheimer's risk scale (score range from 0 to 14) where higher scores confer higher risk

Change from Baseline in Cognitive Aging Composite (CAC) every 6 monthsevery 6 months, for 18 months

Composite Cognitive Battery, including neuropsychological tests related to non-pathological (age-related) cognitive decline.

Change from Baseline in Inflammatory Biomarkers at 18 months18 months

Change in blood serum levels of hs-CRP, fibrinogen, Cystatin C in mg/dL

Change from Baseline in Metabolism Biomarkers at 18 months18 months

Change in blood serum levels of HbA1c and HOMA-IR

Change from Baseline of Australian National University - Alzheimer's Disease Risk Score (ANU-ADRI) at 6 months6 months

Measure longitudinal changes in a validated Alzheimer's risk scale (score range from -13 to 78) where higher scores confer higher risk

Change from Baseline in Cholesterol Biomarkers at 18 months18 months

Change in blood serum levels of cholesterol (total, LDL, HDL) in mg/dL

Change from Baseline on American College of Cardiology / American Heart Association Cardiovascular Risk Percentage at 18 months18 months

Measure longitudinal changes in a validated cardiovascular risk scale (higher percentage confers higher risk).

Change from Baseline in Vitamin D at 18 months18 months

Change in blood serum level of Vitamin D

Trial Locations

Locations (1)

Weill Cornell Medicine

🇺🇸

New York, New York, United States

© Copyright 2025. All Rights Reserved by MedPath